IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 5072 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1
Nancy E. Jones
.2022;()226
[DOI]
2Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation
Myrto Lee,Hoan Ly,Clemens C. Möller,Michael S. Ringel
Clinical Pharmacology & Therapeutics.2019;105(4)886
[DOI]
3Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation
Katherine Dunnington,Natacha Benrimoh,Christine Brandquist,Nadia Cardillo-Marricco,Mike Di Spirito,Julie Grenier
Clinical Pharmacology & Therapeutics.2018;105(4)886
[DOI]
4The ethical justification for inclusion of neonates in pragmatic randomized clinical trials for emergency newborn care
Dan Kabonge Kaye
BMC Pediatrics.2019;19(1)886
[DOI]
5A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes
Susanna Dodd,Ian R. White,Paula Williamson
Trials.2017;18(1)886
[DOI]
6A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes
Susanna Dodd,Ian R. White,Paula Williamson
Trials.2020;18(1)21
[DOI]
7Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia
Andrea Gilmore-Bykovskyi
Journal of the American Geriatrics Society.2018;66(1)S13
[DOI]
8Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability
Alessandro Bosco,Laura Paulauskaite,Ian Hall,Jason Crabtree,Sujata Soni,Asit Biswas,Vivien Cooper,Michaela Poppe,Michael King,Andre Strydom,Michael J. Crawford,Angela Hassiotis,Rosemary Frey
PLOS ONE.2019;14(8)e0221507
[DOI]
9Adaptive trial design: Its growing role in clinical research and implications for pharmacists
Joshua Cirulli,Wesley D. McMillian,Mojdeh Saba,David Stenehjem
American Journal of Health-System Pharmacy.2011;68(9)807
[DOI]
10Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies
Qing Li,Jianchang Lin,Yunzhi Lin
Contemporary Clinical Trials.2020;98(9)106096
[DOI]
11Examining Tensions That Affect the Evaluation of Technology in Health Care: Considerations for System Decision Makers From the Perspective of Industry and Evaluators
Laura Desveaux,James Shaw,Ross Wallace,Onil Bhattacharyya,R Sacha Bhatia,Trevor Jamieson
JMIR Medical Informatics.2017;5(4)e50
[DOI]
12Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists
Kanya K. Shah,Stephen Kogut,Angela Slitt
Journal of Pharmacy Practice.2021;34(3)472
[DOI]
13Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists
Suresh Kumar
Journal of Pharmacy Practice.2021;34(3)472
[DOI]
14How can attrition rates be reduced in cancer drug discovery?
Lucas Moreno,Andrew DJ Pearson
Expert Opinion on Drug Discovery.2013;8(4)363
[DOI]
15Blinding, sham, and treatment effects in randomized controlled trials for back pain in 2000–2019: A review and meta-analytic approach
Brian Freed,Brian Williams,Xiaolu Situ,Victoria Landsman,Jeehyoung Kim,Alex Moroz,Heejung Bang,Jongbae J Park
Clinical Trials.2021;18(3)361
[DOI]
16Drug development challenges and strategies to address emerging and resistant fungal pathogens
Matthew W. McCarthy,Thomas J. Walsh
Expert Review of Anti-infective Therapy.2017;15(6)577
[DOI]
17Including non-concurrent control patients in the analysis of platform trials: is it worth it?
Kim May Lee,James Wason
BMC Medical Research Methodology.2020;20(1)577
[DOI]
18Including non-concurrent control patients in the analysis of platform trials: is it worth it?
David Hong,Pedro C. Barata
BMC Medical Research Methodology.2018;20(1)47
[DOI]
19Including non-concurrent control patients in the analysis of platform trials: is it worth it?
Margaret S. Landis
BMC Medical Research Methodology.2017;25(1)297
[DOI]
20Cardiovascular Nursing Science Priorities
Mariann R. Piano,Nancy T. Artinian,Holli A. DeVon,Susan T. Pressler,Kathleen T. Hickey,Deborah A. Chyun
Journal of Cardiovascular Nursing.2018;33(4)E11
[DOI]
21Adaptive Design of Clinical Trials: A Sequential Learning Approach
Zhengli Wang,Stefanos Zenios
SSRN Electronic Journal.2020;33(4)E11
[DOI]
22Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT
Sudeep Pushpakom,Ruwanthi Kolamunnage-Dona,Claire Taylor,Terry Foster,Catherine Spowart,Marta Garcia-Finana,Graham J Kemp,Thomas Jaki,Saye Khoo,Paula Williamson,Munir Pirmohamed
Efficacy and Mechanism Evaluation.2019;6(6)1
[DOI]
23Brain Organoids: Tiny Mirrors of Human Neurodevelopment and Neurological Disorders
Anuradha Yadav,Brashket Seth,Rajnish Kumar Chaturvedi
The Neuroscientist.2021;27(4)388
[DOI]
24An investigation of the impact of futility analysis in publicly funded trials
Benjamin GO Sully,Steven A Julious,Jon Nicholl
Trials.2014;15(1)388
[DOI]
25Timely evaluation in international development
Jayne Webster,Josephine Exley,James Copestake,Rick Davies,James Hargreaves
Journal of Development Effectiveness.2018;10(4)482
[DOI]
26Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine
Elliott Antman,Scott Weiss,Joseph Loscalzo
Wiley Interdisciplinary Reviews: Systems Biology and Medicine.2012;4(4)367
[DOI]
27Shuffling Adaptive Clinical Trials
Sanjay G. Gokhale,Sankalp Gokhale
American Journal of Therapeutics.2016;23(3)e663
[DOI]
28Computational Drug Repurposing: Current Trends
Berin Karaman,Wolfgang Sippl
Current Medicinal Chemistry.2019;26(28)5389
[DOI]
29Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Miranta Antoniou,Andrea L Jorgensen,Ruwanthi Kolamunnage-Dona,H. Peter Soyer
PLOS ONE.2016;11(2)e0149803
[DOI]
30Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Ruitao Lin,J. Jack Lee
PLOS ONE.2020;11(2)395
[DOI]
31Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Gerfried K.H. Nell
PLOS ONE.2018;11(2)383
[DOI]
32Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Peter G. Stock,Rita Mukhtar,Hila Ghersin,Allison Stover Fiscalini,Laura Esserman
PLOS ONE.2020;11(2)59
[DOI]
33Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Kristiana Salmon,Angela Genge
PLOS ONE.2021;11(2)161
[DOI]
34Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Sarah J. Trenfield,Christine M. Madla,Abdul W. Basit,Simon Gaisford
PLOS ONE.2018;31(2)1
[DOI]
35RCTs and other clinical trial designs in Ayurveda: A review of challenges and opportunities
Pushya A. Gautama
Journal of Ayurveda and Integrative Medicine.2021;12(3)556
[DOI]
36Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial
Franck Pires Cerqueira,Angelo Miguel Cardoso Jesus,Maria Dulce Cotrim
Therapeutic Innovation & Regulatory Science.2019;12(3)216847901983124
[DOI]
37The Future Role of the United States in Global Health
Valentin Fuster,Jendayi Frazer,Megan Snair,Rajesh Vedanthan,Victor Dzau,Jendayi Frazer,Valentin Fuster,Gisela Abbam,Amie Batson,Frederick Burkle,Lynda Chin,Lia Haskin Fernald,Stephanie Ferguson,Peter Lamptey,Ramanan Laxminarayan,Michael Merson,Vasant Narasimhan,Michael Osterholm,Juan Carlos Puyana
Journal of the American College of Cardiology.2017;70(25)3140
[DOI]
38Unique Study Designs in Nephrology: N-of-1 Trials and Other Designs
Joyce P. Samuel,Cynthia S. Bell
Advances in Chronic Kidney Disease.2016;23(6)351
[DOI]
39Nutzenbewertung von digitalen Gesundheitsprodukten (Digital Health) im gesellschaftlichen Erstattungskontext
Urs-Vito Albrecht,Bertolt Kuhn,Jörg Land,Volker E. Amelung,Ute von Jan
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2018;61(3)340
[DOI]
40Implications of comparative effectiveness research for radiation oncology
Justin E. Bekelman,Anand Shah,Stephen M. Hahn
Practical Radiation Oncology.2011;1(2)72
[DOI]
41Implications of comparative effectiveness research for radiation oncology
Gunasakaran Sambandan,Adina Turcu-Stiolica
Practical Radiation Oncology.2019;1(2)323
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow